| scholarly article | Q13442814 |
| P50 | author | Ku-Chung Chen | Q87623435 |
| P2093 | author name string | Tzu-Wen Huang | |
| Chih-Ju Chang | |||
| Chwen-Ming Shih | |||
| Peng-Hsu Chen | |||
| Kuo-Hao Ho | |||
| Ann-Jeng Liu | |||
| Kur-Ta Cheng | |||
| P2860 | cites work | The PD-1 pathway in tolerance and autoimmunity | Q24633549 |
| DrugBank: a knowledgebase for drugs, drug actions and drug targets | Q24650300 | ||
| Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. | Q50778919 | ||
| Inflammatory cytokines IL-17 and TNF-α up-regulate PD-L1 expression in human prostate and colon cancer cells | Q51128749 | ||
| Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients. | Q52757687 | ||
| PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. | Q54427872 | ||
| Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer | Q56965679 | ||
| PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis | Q57083098 | ||
| Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis | Q74184876 | ||
| Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth | Q79856196 | ||
| High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation | Q84014638 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| PD-1/PD-L1 blockades in non-small-cell lung cancer therapy | Q26765024 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Type, density, and location of immune cells within human colorectal tumors predict clinical outcome | Q28131662 | ||
| Cancer immunoediting: from immunosurveillance to tumor escape | Q28212251 | ||
| Genetics of rheumatoid arthritis contributes to biology and drug discovery | Q29417000 | ||
| The immunobiology of cancer immunosurveillance and immunoediting | Q29616246 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Classifying Cancers Based on T-cell Infiltration and PD-L1. | Q35674821 | ||
| RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers | Q36193035 | ||
| FAD-linked Presenilin-1 V97L mutation impede tranport regulation and intracellular Ca(2+) homeostasis under ER stress | Q36492837 | ||
| Tumor-infiltrating B cells come into vogue | Q36525540 | ||
| Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures | Q37422116 | ||
| CD20+ B cells: the other tumor-infiltrating lymphocytes | Q37801779 | ||
| Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer | Q38207907 | ||
| Non-Small Cell Lung Cancer, PD-L1, and the Pathologist | Q38755369 | ||
| PD-1 and PD-L1 antibodies in cancer: current status and future directions | Q38755931 | ||
| Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells | Q38955079 | ||
| The Emerging Role of B Cells in Tumor Immunity | Q38955955 | ||
| Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis | Q39308716 | ||
| B-cell-derived lymphotoxin promotes castration-resistant prostate cancer | Q40440899 | ||
| B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumour immune response by direct and indirect activation of CD8(+) T-cells. | Q40483578 | ||
| Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation. | Q40707762 | ||
| Tumor-infiltrating B cells: The ignored players in tumor immunology. | Q41275029 | ||
| De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent | Q46068963 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | edgeR | Q113334690 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | The Cancer Genome Atlas | Q3979425 |
| adenocarcinoma | Q356033 | ||
| P304 | page(s) | e0208459 | |
| P577 | publication date | 2018-12-06 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Gene landscape and correlation between B-cell infiltration and programmed death ligand 1 expression in lung adenocarcinoma patients from The Cancer Genome Atlas data set | |
| P478 | volume | 13 |
| Q64246388 | The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients | cites work | P2860 |
Search more.